Debiopharm Group (Debiopharm)

Oncology Corporate Profile

HQ Location

Chemin Messidor 5-7
CH - 1002 Lausanne, Switzerland 5911

Company Description

Debiopharm Group™ (Debiopharm) is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. The group in-licenses, develops and/or co-develops promising biological and small molecule drug candidates having reached clinical development phases I, II or III. Debiopharm is also prepared to consider earlier stage candidates. It develops its products for global registration and maximum commercial potential. The products are out-licensed to pharmaceutical partners for sales and marketing. Besides drug development, Debiopharm Group™ has recently embarked in the field of companion diagnostics with a view to progressing in the area of personalised medicine.


This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
triptorelin / Debio 8206GnRH antagonist (oral)1st line metastatic Prostate cancerIII
Debio 0932 (CUDC-305)Hsp90 inhibitorVarious cancer typesICuris
Debio 1347 (CH5183284)selective FGFR 1, 2, 3 inhibitorVarious cancer typesI
Debio 0929GPCR InhibitorVarious cancer typesPreclinical
Debio 0617multikinase inhibitor of undisclosed oncology targetsVarious cancer typesPreclinicalAurigene
Debio 1144 (ASP-08126)multiple tyrosine kinase inhibitorVarious cancer typesPreclinicalAscepion
Debio 1141RNA antagonistUrothelial carcinomaResearchMarina Biotech, Inc.

View additional information on product candidates here »


Recent News Headlines

There are no news items to display